Gyre Therapeutics (GYRE) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 4, 2025, to be held virtually, with voting on director elections, executive compensation, and auditor ratification.

• Only stockholders of record as of April 10, 2025, are eligible to vote, with each share entitled to one vote per proposal.

• The company completed a business combination in October 2023, changing its name and ticker symbol.

• Forward-looking statements are included, subject to risks and uncertainties as described in the annual report.

Voting matters and shareholder proposals

• Stockholders will vote on electing three Class I directors, a non-binding advisory vote on executive compensation, and ratification of Grant Thornton Zhitong as independent auditor for 2025.

• The board recommends voting FOR all director nominees and proposals.

• No other matters are currently anticipated, but proxies may vote on additional items if they arise.

• Shareholder proposals for the 2026 meeting must be submitted by December 22, 2025, to be included in the proxy statement.

Board of directors and corporate governance

• The board consists of eight directors divided into three classes with staggered three-year terms.

• Four directors are considered independent; the company qualifies as a "controlled company" under Nasdaq rules and relies on certain governance exemptions.

• The board has Audit, Compensation, and Nominating Committees, each with defined responsibilities and independent membership where required.

• The board encourages director attendance at meetings and has adopted a Code of Business Conduct and Ethics.